{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:55:21Z","timestamp":1789206921079,"version":"build-2803163510"},"reference-count":131,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1097\/mjt.0b013e3181df8ad2","type":"journal-article","created":{"date-parts":[[2010,6,18]],"date-time":"2010-06-18T08:21:10Z","timestamp":1276849270000},"page":"402-417","source":"Crossref","is-referenced-by-count":12,"title":["Current and Future Therapeutic Options for the Management of Gout"],"prefix":"10.1097","volume":"17","author":[{"given":"Andrew","family":"Whelton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210202","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II.","volume":"58","author":"Lawrence","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R2-9-20210202","first-page":"2403","article-title":"Epidemiology of gout: is the incidence rising?","volume":"29","author":"Arromdee","year":"2002","journal-title":"J Rheumatol"},{"key":"R3-9-20210202","first-page":"1582","article-title":"Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population.","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"R4-9-20210202","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy.","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R5-9-20210202","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/BOR.0b013e3282f54d03","article-title":"We can make gout management more successful now.","volume":"20","author":"Becker","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"R6-9-20210202","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1002\/art.23803","article-title":"Treatment-failure gout: a moving target.","volume":"58","author":"Edwards","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R7-9-20210202","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/rheumatology\/kep047","article-title":"Perceptions of disease and health-related quality of life among patients with gout.","volume":"48","author":"Lee","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"R8-9-20210202","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar1906","article-title":"A concise history of gout and hyperuricemia and their treatment.","volume":"8","author":"Nuki","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R9-9-20210202","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/art.20761","article-title":"Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey.","volume":"52","author":"Choi","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R10-9-20210202","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/art.23245","article-title":"Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey.","volume":"59","author":"Choi","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R11-9-20210202","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/ard.33.3.276","article-title":"Effect of oral fructose on urate production.","volume":"33","author":"Emmerson","year":"1974","journal-title":"Ann Rheum Dis"},{"key":"R12-9-20210202","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/HYPERTENSIONAHA.107.091041","article-title":"Intake of added sugar and sugar-sweetened drink and serum uric acid concentration in US men and women.","volume":"50","author":"Gao","year":"2007","journal-title":"Hypertension"},{"key":"R13-9-20210202","doi-asserted-by":"crossref","first-page":"83","DOI":"10.7150\/ijms.4.83","article-title":"Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.","volume":"4","author":"Cammalleri","year":"2007","journal-title":"Int J Med Sci"},{"key":"R14-9-20210202","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/oxfordjournals.molbev.a004123","article-title":"Loss of urate oxidase activity in hominoids and its evolutionary implications.","volume":"19","author":"Oda","year":"2002","journal-title":"Mol Biol Evol"},{"key":"R15-9-20210202","first-page":"215","article-title":"Hyperuricemia and gout: new insights into pathogenesis and treatment.","volume":"65","author":"Pillinger","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"R16-9-20210202","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/art.20821","article-title":"Beer, liquor, and wine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey.","volume":"51","author":"Choi","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R17-9-20210202","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","article-title":"Alcohol intake and risk of incident gout in men: a prospective study.","volume":"363","author":"Choi","year":"2004","journal-title":"Lancet"},{"key":"R18-9-20210202","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.","volume":"82","author":"Campion","year":"1987","journal-title":"Am J Med"},{"key":"R19-9-20210202","first-page":"1501","article-title":"The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study.","volume":"27","author":"Lin","year":"2000","journal-title":"J Rheumatol"},{"key":"R20-9-20210202","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/ard.33.4.313","article-title":"Factors affecting urate solubility in vitro.","volume":"33","author":"Kippen","year":"1974","journal-title":"Ann Rheum Dis"},{"key":"R21-9-20210202","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","article-title":"EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R22-9-20210202","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2165\/00003495-200464210-00003","article-title":"Management of acute and chronic gouty arthritis: present state-of-the-art.","volume":"64","author":"Schlesinger","year":"2004","journal-title":"Drugs"},{"key":"R23-9-20210202","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.amjmed.2003.09.045","article-title":"Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome.","volume":"116","author":"Davidson","year":"2004","journal-title":"Am J Med"},{"key":"R24-9-20210202","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","article-title":"Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?","volume":"57","author":"Perez-Ruiz","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R25-9-20210202","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2125.1987.tb03132.x","article-title":"Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs.","volume":"24","author":"Bellamy","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"R26-9-20210202","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.071229","article-title":"Quality of life and disability in patients with treatment-failure gout.","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"issue":"Suppl 1","key":"R27-9-20210202","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar1908","article-title":"The inflammatory process of gout and its treatment.","volume":"8","author":"Cronstein","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R28-9-20210202","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1172\/JCI29404","article-title":"Gout: new insights into an old disease.","volume":"116","author":"Martinon","year":"2006","journal-title":"J Clin Invest"},{"key":"R29-9-20210202","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/art.22938","article-title":"The role of interleukin-1 and the inflammasome in gout: implications for therapy.","volume":"56","author":"Pope","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R30-9-20210202","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1046\/j.1523-1755.2003.t01-2-00171.x","article-title":"The association between gout and nephrolithiasis in men: The Health Professionals Follow-Up Study.","volume":"64","author":"Kramer","year":"2003","journal-title":"Kidney Int"},{"key":"R31-9-20210202","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/ajkd.2002.33911","article-title":"The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994.","volume":"40","author":"Kramer HM and Curhan","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R32-9-20210202","first-page":"2189","article-title":"Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed?","volume":"32","author":"Alvarez-Nemegyei","year":"2005","journal-title":"J Rheumatol"},{"key":"R33-9-20210202","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000168799","article-title":"Renal function in gout patients.","volume":"15","author":"Tarng","year":"1995","journal-title":"Am J Nephrol"},{"key":"R34-9-20210202","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1681\/ASN.2004030208","article-title":"Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study.","volume":"16","author":"Domrongkitchaiporn","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R35-9-20210202","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1681\/ASN.2008010080","article-title":"Elevated uric acid increases the risk for kidney disease.","volume":"19","author":"Obermayr","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R36-9-20210202","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10067-007-0750-7","article-title":"Ischemia heart disease and greater waist circumference are risk factors of renal function deterioration in male gout patients.","volume":"27","author":"Su","year":"2008","journal-title":"Clin Rheumatol"},{"key":"R37-9-20210202","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1751-7176.2009.00101.x","article-title":"Uric acid as a marker for renal dysfunction in hypertensive women on diuretic and nondiuretic therapy.","volume":"11","author":"Borges","year":"2009","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R38-9-20210202","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/HJH.0b013e328303205d","article-title":"Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency.","volume":"26","author":"Eraranta","year":"2008","journal-title":"J Hypertens"},{"key":"R39-9-20210202","doi-asserted-by":"crossref","first-page":"F991","DOI":"10.1152\/ajprenal.00283.2001","article-title":"Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.","volume":"282","author":"Mazzali","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"R40-9-20210202","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ndt\/gfm783","article-title":"Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.","volume":"23","author":"Sanchez-Lozada","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R41-9-20210202","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/hy1101.092839","article-title":"Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.","volume":"38","author":"Mazzali","year":"2001","journal-title":"Hypertension"},{"key":"R42-9-20210202","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00074.x","article-title":"Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats.","volume":"67","author":"Sanchez-Lozada","year":"2005","journal-title":"Kidney Int"},{"key":"R43-9-20210202","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","article-title":"A role for uric acid in the progression of renal disease.","volume":"13","author":"Kang","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R44-9-20210202","doi-asserted-by":"crossref","first-page":"F1105","DOI":"10.1152\/ajprenal.00170.2002","article-title":"Mild hyperuricemia induces glomerular hypertension in normal rats.","volume":"283","author":"Sanchez-Lozada","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"R45-9-20210202","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1161\/01.HYP.0000150785.39055.e8","article-title":"Resurrection of uric acid as a causal risk factor in essential hypertension.","volume":"45","author":"Johnson","year":"2005","journal-title":"Hypertension"},{"key":"R46-9-20210202","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1161\/01.HYP.0000248752.08807.4c","article-title":"Uric acid and the development of hypertension: the normative aging study.","volume":"48","author":"Perlstein","year":"2006","journal-title":"Hypertension"},{"key":"R47-9-20210202","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1203\/PDR.0b013e318183fd7c","article-title":"Serum uric acid and ambulatory blood pressure in children with primary hypertension.","volume":"64","author":"Jones","year":"2008","journal-title":"Pediatr Res"},{"key":"R48-9-20210202","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1161\/01.HYP.0000085858.66548.59","article-title":"Hyperuricemia in childhood primary hypertension.","volume":"42","author":"Feig","year":"2003","journal-title":"Hypertension"},{"key":"R49-9-20210202","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1161\/01.HYP.0000249768.26560.66","article-title":"Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study.","volume":"48","author":"Mellen","year":"2006","journal-title":"Hypertension"},{"key":"R50-9-20210202","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/01.HYP.0000150784.92944.9a","article-title":"Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence.","volume":"45","author":"Sundstrom","year":"2005","journal-title":"Hypertension"},{"key":"R51-9-20210202","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/01.HYP.0000254480.64564.b6","article-title":"Hyperuricemia and incidence of hypertension among men without metabolic syndrome.","volume":"49","author":"Krishnan","year":"2007","journal-title":"Hypertension"},{"key":"R52-9-20210202","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.amjmed.2006.06.040","article-title":"Prevalence of the metabolic syndrome in individuals with hyperuricemia.","volume":"120","author":"Choi","year":"2007","journal-title":"Am J Med"},{"key":"R53-9-20210202","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.metabol.2008.01.030","article-title":"Uric acid and the development of metabolic syndrome in women and men.","volume":"57","author":"Sui","year":"2008","journal-title":"Metabolism"},{"key":"R54-9-20210202","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/art.22466","article-title":"Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey.","volume":"57","author":"Choi","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R55-9-20210202","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2337\/dc07-1276","article-title":"High serum uric acid as a novel risk factor for type 2 diabetes.","volume":"31","author":"Dehghan","year":"2008","journal-title":"Diabetes Care"},{"key":"R56-9-20210202","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archinte.168.10.1104","article-title":"Long-term cardiovascular mortality among middle-aged men with gout.","volume":"168","author":"Krishnan","year":"2008","journal-title":"Arch Intern Med"},{"key":"R57-9-20210202","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/rheumatology\/ken305","article-title":"Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile.","volume":"47","author":"Choi","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"R58-9-20210202","first-page":"73","article-title":"Cardiovascular disease risk factor assessment and management in gout: an analysis using guideline-based electronic clinical decision support.","volume":"121","author":"Colvine","year":"2008","journal-title":"N Z Med J"},{"key":"R59-9-20210202","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease.","volume":"116","author":"Choi HK and Curhan","year":"2007","journal-title":"Circulation"},{"key":"R60-9-20210202","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/rheumatology\/kep364","article-title":"Gout: an independent risk factor for all-cause and cardiovascular mortality.","volume":"49","author":"Kuo","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R61-9-20210202","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/art.24612","article-title":"Hyperuricemia and risk of stroke: a systematic review and meta-analysis.","volume":"61","author":"Kim","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R62-9-20210202","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R64-9-20210202","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R66-9-20210202","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1172\/JCI28075","article-title":"MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals.","volume":"116","author":"Chen","year":"2006","journal-title":"J Clin Invest"},{"key":"R67-9-20210202","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/ard.2009.109355","article-title":"Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis.","volume":"68","author":"Torres","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R68-9-20210202","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","article-title":"The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.","volume":"68","author":"Terkeltaub","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R69-9-20210202","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout.","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"R70-9-20210202","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li-Yu","year":"2001","journal-title":"J Rheumatol"},{"key":"R71-9-20210202","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares: analysis from managed care data.","volume":"12","author":"Sarawate","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"R72-9-20210202","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4615-5381-6_3","article-title":"Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment.","volume":"431","author":"Yamanaka","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"R73-9-20210202","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R74-9-20210202","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/BOR.0b013e328335ef38","article-title":"A prescription for lifestyle change in patients with hyperuricemia and gout.","volume":"22","author":"Choi","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"R75-9-20210202","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R76-9-20210202","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/archinte.165.7.742","article-title":"Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study.","volume":"165","author":"Choi","year":"2005","journal-title":"Arch Intern Med"},{"key":"R77-9-20210202","first-page":"1350","article-title":"Gout, diet, and the insulin resistance syndrome.","volume":"29","author":"Fam","year":"2002","journal-title":"J Rheumatol"},{"key":"R78-9-20210202","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2006.060368","article-title":"Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.","volume":"66","author":"Pascual","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R79-9-20210202","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00296-009-1002-8","article-title":"Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved.","volume":"30","author":"Thiele","year":"2010","journal-title":"Rheumatol Int"},{"key":"R80-9-20210202","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/15257770802136032","article-title":"Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy.","volume":"27","author":"Becker","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"R81-9-20210202","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"key":"R82-9-20210202","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout.","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"R83-9-20210202","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R84-9-20210202","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat for the treatment of hyperuricemia and gout: the CONFIRMS trial.","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"R85-9-20210202","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective.","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R86-9-20210202","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/rheumatology\/26.6.445","article-title":"Plasma oxipurinol concentrations during allopurinol therapy.","volume":"26","author":"Emmerson","year":"1987","journal-title":"Br J Rheumatol"},{"key":"R87-9-20210202","first-page":"82","article-title":"Gout in 2006: the perfect storm.","volume":"64","author":"Terkeltaub","year":"2006","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"R88-9-20210202","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"R90-9-20210202","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"R91-9-20210202","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"A randomised controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300-600 mg\/day versus benzbromarone 100-200 mg\/day in patients with gout.","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R93-9-20210202","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"R94-9-20210202","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00124743-199904000-00003","article-title":"Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study.","volume":"5","author":"Perez-Ruiz","year":"1999","journal-title":"J Clin Rheumatol"},{"key":"R95-9-20210202","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R96-9-20210202","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/BOR.0b013e328325bd94","article-title":"Update on emerging urate-lowering therapies.","volume":"21","author":"Chohan","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"R97-9-20210202","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/B:CARD.0000015855.02485.e3","article-title":"Cardiovascular drugs and serum uric acid.","volume":"17","author":"Reyes","year":"2003","journal-title":"Cardiovasc Drugs Ther"},{"key":"R98-9-20210202","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/ard.62.6.572","article-title":"Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and\/or losartan on uric acid metabolism.","volume":"62","author":"Takahashi","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R100-9-20210202","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","article-title":"Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase.","volume":"76","author":"Takano","year":"2005","journal-title":"Life Sci"},{"key":"R101-9-20210202","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout.","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"R102-9-20210202","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R103-9-20210202","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1081\/NCN-200027372","article-title":"Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.","volume":"23","author":"Becker","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"R104-9-20210202","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1081\/NCN-200027377","article-title":"PK\/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment.","volume":"23","author":"Hoshide","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"R105-9-20210202","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00045391-200501000-00005","article-title":"Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.","volume":"12","author":"Mayer","year":"2005","journal-title":"Am J Ther"},{"key":"R108-9-20210202","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.leu.2403566","article-title":"Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial.","volume":"19","author":"Jeha","year":"2005","journal-title":"Leukemia"},{"key":"R109-9-20210202","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","article-title":"A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.","volume":"97","author":"Goldman","year":"2001","journal-title":"Blood"},{"key":"R110-9-20210202","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1517\/14656560902781972","article-title":"A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function.","volume":"10","author":"Malaguarnera","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"R111-9-20210202","first-page":"179","article-title":"Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.","volume":"11","author":"De Angelis","year":"2007","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R112-9-20210202","first-page":"2093","article-title":"Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study.","volume":"34","author":"Richette","year":"2007","journal-title":"J Rheumatol"},{"key":"R113-9-20210202","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R114-9-20210202","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R115-9-20210202","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study.","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R116-9-20210202","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/art.23993","article-title":"Resolution of gouty tophi after twelve weeks of pegloticase treatment.","volume":"58","author":"Baraf","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R121-9-20210202","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels.","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"R122-9-20210202","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/art.21499","article-title":"Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population.","volume":"54","author":"Graessler","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R123-9-20210202","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1681\/ASN.2006030264","article-title":"Human vascular smooth muscle cells express a urate transporter.","volume":"17","author":"Price","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R124-9-20210202","doi-asserted-by":"crossref","first-page":"26834","DOI":"10.1074\/jbc.C800156200","article-title":"Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans.","volume":"283","author":"Anzai","year":"2008","journal-title":"J Biol Chem"},{"key":"R125-9-20210202","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1371\/journal.pmed.0050197","article-title":"SLC2A9 is a high-capacity urate transporter in humans.","volume":"5","author":"Caulfield","year":"2008","journal-title":"PLoS Med"},{"key":"R126-9-20210202","doi-asserted-by":"crossref","first-page":"16229","DOI":"10.1074\/jbc.M312226200","article-title":"Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking.","volume":"279","author":"Augustin","year":"2004","journal-title":"J Biol Chem"},{"key":"R127-9-20210202","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/rheumatology\/ken460","article-title":"Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout.","volume":"48","author":"Dalbeth N and Merriman","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R128-9-20210202","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/ng.107","article-title":"SLC2A9 influences uric acid concentrations with pronounced sex-specific effects.","volume":"40","author":"Doring","year":"2008","journal-title":"Nat Genet"},{"key":"R129-9-20210202","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(08)61343-4","article-title":"Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.","volume":"372","author":"Dehghan","year":"2008","journal-title":"Lancet"},{"key":"R130-9-20210202","doi-asserted-by":"crossref","first-page":"F327","DOI":"10.1152\/ajprenal.00133.2004","article-title":"Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites.","volume":"288","author":"Van Aubel","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"R132-9-20210202","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1124\/jpet.105.092684","article-title":"The dual actions of morin (3,5,7,2,4-pentahydroxyflavone) as a hypouricemic agent: uricosuric effect and xanthine oxidase inhibitory activity.","volume":"316","author":"Yu","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"R133-9-20210202","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1124\/dmd.106.012187","article-title":"Morin (3,5,7,2,4-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells.","volume":"35","author":"Yu","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"R134-9-20210202","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jep.2005.08.040","article-title":"Effects of cassia oil on serum and hepatic uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver.","volume":"103","author":"Zhao","year":"2006","journal-title":"J Ethnopharmacol"},{"key":"R135-9-20210202","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jep.2004.03.037","article-title":"Effects of Biota orientalis extract and its flavonoid constituents, quercetin and rutin on serum uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver.","volume":"93","author":"Zhu","year":"2004","journal-title":"J Ethnopharmacol"},{"key":"R136-9-20210202","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jep.2009.12.035","article-title":"The dual actions of Sanmiao wan as a hypouricemic agent: down-regulation of hepatic XOD and renal mURAT1 in hyperuricemic mice.","volume":"128","author":"Wang","year":"2010","journal-title":"J Ethnopharmacol"},{"key":"R137-9-20210202","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jep.2004.01.013","article-title":"Inhibition of MAO A and B by some plant-derived alkaloids, phenols and anthraquinones.","volume":"91","author":"Kong","year":"2004","journal-title":"J Ethnopharmacol"},{"key":"R138-9-20210202","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1055\/s-2008-1081344","article-title":"The dual actions of Paederia scandens extract as a hypouricemic agent: xanthine oxidase inhibitory activity and uricosuric effect.","volume":"74","author":"Yan","year":"2008","journal-title":"Planta Med"},{"key":"R139-9-20210202","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ard.41.1.59","article-title":"Allopurinol treatment and its effect on renal function in gout: a controlled study.","volume":"41","author":"Gibson","year":"1982","journal-title":"Ann Rheum Dis"},{"key":"R140-9-20210202","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s11255-007-9253-3","article-title":"Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions.","volume":"39","author":"Kanbay","year":"2007","journal-title":"Int Urol Nephrol"},{"key":"R141-9-20210202","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","article-title":"Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.","volume":"47","author":"Siu","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R142-9-20210202","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000045783","article-title":"Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts.","volume":"86","author":"Perez-Ruiz","year":"2000","journal-title":"Nephron"},{"key":"R143-9-20210202","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000105142","article-title":"The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease.","volume":"27","author":"Talaat","year":"2007","journal-title":"Am J Nephrol"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00045391-201007000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:26:03Z","timestamp":1786040763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045391-201007000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":131,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3181df8ad2","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}